Page 56 - AN-4-2

Advanced Neurology George Cotzias and L-DOPA therapy

as well as Dr. Nikolaos Lazaridis and Dr. Anastasios doi: 10.1002/mds.26120
Mylonas for their assistance. 8. Ngwuluka N, Pillay V, Du Toit LC, et al. L-DOPA Delivery
systems: Advancements in delivery of the gold standard.
Funding Expert Opin Drug Deliv. 2010;7:203-224.
None. doi: 10.1517/17425240903483166
Conflict of interest 9. Schulz JB, Hausmann L, Hardy J. 199 years of Parkinson
disease-what have we learned and what is the path to the
The authors declare that they have no competing interests. future? J Neurochem. 2016;13(9 Suppl):3-7.
Author contributions doi: 10.1111/jnc.13733
10. Albin LR, Leventhal KD. The missing, the short, and the
Conceptualization: Konstantina Kotsaki long: L-DOPA responses and dopamine actions. Ann Neurol.
Writing–original draft: All authors 2017;82:4-19.
Writing–review & editing: All authors
doi: 10.1002/ana.24961
Ethics approval and consent to participate 11. Berthet A, Bezard E. Dopamine receptors and L-DOPA-induced
dyskinesia. Parkinsonism Relat Disord. 2009;15:S8-S12.
Not applicable.
doi: 10.1016/S1353-8020(09)70827-2
Consent for publication 12. Bonner N, Bozzi S, Morgan L, et al. Patients’ experiences of

Not applicable. Parkinson’s disease: A qualitative study in glucocerebrosidase
and idiopathic Parkinson’s disease. J Patient Rep Outcomes.
Availability of data 2020;4(65):1-14.

Not applicable. doi: 10.1186/s41687-020-00230-9
13. Encarnacion VE, Hauser AR. L-DOPA-induced dyskinesias
References in Parkinson’s disease: Etiology, impact on quality of life,
and treatments. Eur Neurol. 2008;60:57-66.
1. Blonder XL. Historical and cross-cultural perspectives on
Parkinson’s disease. J Complement Integr Med. 2018;15:1-15. doi: 10.1159/000131893
doi: 10.1515/jcim-2016-0065 14. Ferreira FFA, Meira M, Lemuchi ML, et al. Most Utilized rodent
models for Alzheimer’s and Parkinson’s disease: A critical
2. Fahn S. The medical treatment of Parkinson disease from review of the past 5 years. Adv. Neurol. 2024;3(3):1-19.
James Parkinson to George Cotzias. Mov Disord. 2015;30:4-18.
doi: 10.36922/an.2903
doi: 10.1002/mds.26102
15. Feyder M, Bonito-Oliva A, Fisone G. L-DOPA-induced
3. Goldman GJ, Goetz GC. History of Parkinson’s disease. dyskinesia and abnormal signaling in striatal medium
Handb Clin Neurol. 2007;83:109-128. spiny neurons: Focus on dopamine D1 receptor-mediated
doi: 10.1016/S0072-9752(07)83005-3 transmission. Front Behav Neurosci. 2011;5:71.
4. Fahn S. The 200-year journey of Parkinson disease: doi: 10.3389/fnbeh.2011.00071
Reflecting on the past and looking towards the future. 16. Hornykiewicz O. L-DOPA: From a biologically inactive
Parkinsonism Relat Disord. 2017;30:S1-S5. amino acid to a successful therapeutic agent. Amino Acids.
doi: 10.1016/j.parkreldis.2017.07.020 2002;23:65-70.
5. Goole J, Amighi K. L-DOPA delivery systems for the doi: 10.1007/s00726-001-0111-9
treatment of Parkinson’s disease: An overview. Int J Pharm. 17. Juri C, Chana P. L-DOPA for Parkinson’s disease. What have
2009;380:1-15. we learned? (L-DOPA en la enfermedad de Parkinson. ¿Qué
doi: 10.1016/j.ijpharm.2009.07.026 hemos aprendido?). Rev Med Chil. 2006;134:893-901.
6. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression 18. Lew M. Overview of Parkinson’s disease. Pharmacotherapy.
and mortality. Neurology. 1967;17(5):427-442. 2007;27:155S-160S.
doi: 10.1212/wnl.17.5.427 doi: 10.1592/phco.27.12part2.155S
7. Lees JA, Tolosa E, Olanow WC. Four pioneers of L-DOPA 19. LeWitt AP, Fahn S. L-DOPA therapy for Parkinson disease:
treatment: Arvid Carlsson, Oleh Hornykiewicz, George A look backward and forward. Neurology. 2016;86:2-12.
Cotzias, and Melvin Yahr. Mov Disord. 2014;30:19-36. doi: 10.1212/WNL.0000000000002509

Volume 4 Issue 2 (2025) 50 doi: 10.36922/an.5177